Bleomycin for orbital and peri-orbital veno-lymphatic malformations - A systematic review.
Preferred Reporting Items for Systematic Reviews and Meta-Analyses
Venolymphatic malformations
lymphatic malformations
venous malformations
Journal
Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences
ISSN: 2385-2011
Titre abrégé: Interv Neuroradiol
Pays: United States
ID NLM: 9602695
Informations de publication
Date de publication:
Apr 2021
Apr 2021
Historique:
pubmed:
12
11
2020
medline:
25
11
2021
entrez:
11
11
2020
Statut:
ppublish
Résumé
Orbital and peri-orbital venolymphatic malformations (VLM) are low flow vascular malformations. Intralesional bleomycin is now commonly being used to treat such malformations. The purpose of this systematic review is to synthesize evidence on the safety and efficacy of bleomycin/pingyangmycin sclerotherapy for the treatment of orbital and peri-orbital VLM. We searched Medline, Embase, Scopus and Cochrane database for studies reporting outcomes of bleomycin/pingyangmycin sclerotherapy for orbital and peri-orbital VLM between 1974 to April 5th, 2019. Nine retrospective cohort studies enrolling 132 patients were included. Two reviewers independently screened and extracted data and assessed the risk of bias. Predefined outcome measures were subjective and objective reduction of the lesion and associated complications. Subjective reduction of the lesions was seen in 96.2% of the studies. Objective reduction of the lesion and symptomatic improvement were reported in 91.6 and 95% of the studies respectively. Non responders were 9.0%. Minor adverse events were reported in 18.1% of the studies. Major complications like pulmonary toxicity or pulmonary fibrosis was not encountered in any of the included studies. Quality of evidence was generally low. Bleomycin/pingyangmycin sclerotherapy is very effective and relatively safe for the treatment of orbital and periorbital VLM and is not associated with any major side effects including pulmonary fibrosis.
Sections du résumé
BACKGROUND
BACKGROUND
Orbital and peri-orbital venolymphatic malformations (VLM) are low flow vascular malformations. Intralesional bleomycin is now commonly being used to treat such malformations.
OBJECTIVE
OBJECTIVE
The purpose of this systematic review is to synthesize evidence on the safety and efficacy of bleomycin/pingyangmycin sclerotherapy for the treatment of orbital and peri-orbital VLM.
METHODS
METHODS
We searched Medline, Embase, Scopus and Cochrane database for studies reporting outcomes of bleomycin/pingyangmycin sclerotherapy for orbital and peri-orbital VLM between 1974 to April 5th, 2019. Nine retrospective cohort studies enrolling 132 patients were included. Two reviewers independently screened and extracted data and assessed the risk of bias. Predefined outcome measures were subjective and objective reduction of the lesion and associated complications.
RESULTS
RESULTS
Subjective reduction of the lesions was seen in 96.2% of the studies. Objective reduction of the lesion and symptomatic improvement were reported in 91.6 and 95% of the studies respectively. Non responders were 9.0%. Minor adverse events were reported in 18.1% of the studies. Major complications like pulmonary toxicity or pulmonary fibrosis was not encountered in any of the included studies. Quality of evidence was generally low.
CONCLUSION
CONCLUSIONS
Bleomycin/pingyangmycin sclerotherapy is very effective and relatively safe for the treatment of orbital and periorbital VLM and is not associated with any major side effects including pulmonary fibrosis.
Identifiants
pubmed: 33175616
doi: 10.1177/1591019920972514
pmc: PMC8050523
doi:
Substances chimiques
Sclerosing Solutions
0
Bleomycin
11056-06-7
Types de publication
Journal Article
Systematic Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
291-297Références
J Neurointerv Surg. 2019 Jan;11(1):57-61
pubmed: 29674482
PLoS Med. 2009 Jul 21;6(7):e1000100
pubmed: 19621070
Orbit. 2019 Feb;38(1):30-36
pubmed: 29902086
West J Nurs Res. 2013 Nov;35(10):1249-50
pubmed: 23759794
J Pediatr Hematol Oncol. 2015 Nov;37(8):e447-52
pubmed: 26422284
Ophthalmic Plast Reconstr Surg. 2014 May-Jun;30(3):e65-7
pubmed: 24025999
BMJ. 2011 Oct 18;343:d5928
pubmed: 22008217
J Clin Neurosci. 2015 May;22(5):877-82
pubmed: 25796957
Pediatr Pulmonol. 2010 Feb;45(2):192-6
pubmed: 19953580
Acta Otolaryngol. 2010 Aug;130(8):942-51
pubmed: 20105108
Phlebology. 2019 Jun;34(5):355-361
pubmed: 30336759
Surv Ophthalmol. 2015 Sep-Oct;60(5):383-405
pubmed: 26077629
Plast Reconstr Surg. 2016 Jan;137(1):244-256
pubmed: 26710030
J AAPOS. 2017 Apr;21(2):146-151
pubmed: 28300684
Pulm Pharmacol Ther. 2005;18(5):363-6
pubmed: 15939315
Br J Ophthalmol. 2013 Jun;97(6):739-45
pubmed: 23603483
J Plast Reconstr Aesthet Surg. 2016 Mar;69(3):295-304
pubmed: 26723834
AJR Am J Roentgenol. 2008 Apr;190(4):966-71
pubmed: 18356443
Cardiovasc Intervent Radiol. 2014 Aug;37(4):977-89
pubmed: 24196269
Eye (Lond). 2018 Jan;32(1):152-155
pubmed: 28776595
AJNR Am J Neuroradiol. 2018 Feb;39(2):350-354
pubmed: 29191875
Molecules. 2016 Jun 30;21(7):
pubmed: 27376254
JAMA Ophthalmol. 2014 Aug;132(8):942-8
pubmed: 24723045
Ocul Oncol Pathol. 2019 Oct;5(6):412-417
pubmed: 31768364